Study Overview and Journal Publication
The study "Stereotactic Body Radiation Therapy for Symptomatic Benign Spinal Tumors: A Single-Center Retrospective Experience" was published in *Advances in Radiation Oncology* in 2026. The research team, led by Susko et al., evaluated the efficacy and safety of stereotactic body radiation therapy (SBRT) for treating symptomatic benign spinal tumors (BSTs). The study was conducted at a single institution between 2010 and 2021, analyzing data from 31 patients with 36 BSTs. The authors emphasized that BSTs, while uncommon, can cause significant morbidity due to their location and size. Surgical resection is typically the primary treatment, but SBRT is considered for nonsurgical candidates or those who have progressed after surgery. The study aimed to assess local control, toxicity, and symptomatic outcomes following SBRT, contributing to the evidence base for this treatment modality.
Study Design and Patient Characteristics
The retrospective analysis included 31 patients with 36 benign spinal tumors, categorized by location and histology. Tumors were distributed as 16 in the cervical spine (44%), 13 in the thoracic spine (36%), and 7 in the lumbosacral region (20%). Histological subtypes included 14 schwannomas (39%), 12 meningiomas (33%), 8 hemangiomas (22%), and smaller numbers of melanocytic tumors and neurofibromas. Patients received SBRT with a median prescribed dose of 25 Gy in 5 fractions, ranging from 18-40 Gy across 3-5 fractions. Of the treated lesions, 47% had prior surgical management, while 53% were treated with SBRT as the initial intervention. The study reported a median imaging follow-up of 49 months and clinical follow-up of 83 months, with 86% of assessable patients showing stable or improved symptoms at 12 months. No high-grade toxicities (grade 3 or above) were observed, though transient side effects like fatigue and pain flares occurred in 17% and 14% of cases, respectively.
Key Findings and Outcomes
The study found that SBRT demonstrated high rates of symptomatic stability or improvement in patients with symptomatic benign spinal tumors. At 12 months, 86% of assessable patients experienced stable or improved symptoms in the treated lesions. Imaging follow-up revealed no local failures, with a median follow-up of 49 months, though the authors noted that longer-term data are needed to confirm sustained control. Two patients showed progressive disease on imaging, but no cases of high-grade toxicity (grade 3 or above) were reported. The most common adverse events were transient fatigue (17%) and pain flares (14%). The study also found no significant differences in outcomes based on whether SBRT was used as a primary treatment or after prior surgery. The authors concluded that SBRT is a well-tolerated option for symptomatic BSTs, with acceptable local control and minimal toxicity, though they acknowledged limitations such as the small sample size and short follow-up period compared to long-term tumor behavior.
Study Limitations and Context
The authors highlighted several limitations of their study. The retrospective design and single-center nature may limit generalizability, as outcomes could vary across institutions. The sample size of 31 patients with 36 tumors is relatively small, and the median follow-up of 49 months may not capture long-term tumor behavior, particularly given the slow growth of benign spinal tumors. Additionally, the study did not compare SBRT directly with surgical management, focusing instead on outcomes for patients who received radiation therapy. The authors noted that while prior studies of stereotactic radiosurgery (SRS) for benign intracranial tumors show high local control rates, similar data for spinal tumors remain limited. They emphasized the need for larger, prospective studies to validate these findings and better understand the long-term efficacy and safety of SBRT for BSTs. Despite these limitations, the results suggest SBRT as a viable alternative for patients who are not surgical candidates or who prefer non-invasive treatment options.
Implications for Spine Health and Treatment
This study contributes to the growing body of evidence supporting the use of stereotactic body radiation therapy (SBRT) for symptomatic benign spinal tumors. While surgical resection remains the standard of care for many patients, SBRT offers a non-invasive alternative with favorable toxicity profiles and high rates of symptomatic improvement. The findings align with existing data on SRS for benign intracranial tumors, suggesting similar outcomes for spinal lesions. However, the authors caution that longer follow-up is necessary to confirm sustained local control, as benign tumors may exhibit delayed progression. The study also underscores the importance of individualized treatment decisions, considering factors such as tumor type, patient health, and preferences. For chiropractors and spine care professionals, this research highlights the evolving landscape of non-surgical interventions for spinal conditions, emphasizing the need for multidisciplinary approaches to patient management. Further research is needed to establish SBRT's role in broader clinical practice and to compare its efficacy with other treatment modalities.